Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

NCT00202930 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Closed early due to low accrual.

Conditions

Neuroblastoma
Opsoclonus-myoclonus

Interventions

DRUG: anti-CD20 (Rituximab)

Sponsor

Jean M. Tersak, M.D.

Collaborators

[object Object]